IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease

• Published in: Immunogenetics (New York) Vol. 49; no. 6; pp. 527 - 531
• Main Authors: Nemetz, A, Nosti-Escanilla, M P, Molnár, T, Köpe, A, Kovács, A, Fehér, J, Tulassay, Z, Nagy, F, García-González, M A, Peña, A S
• Format: Journal Article
• Language: English
• Published: United States 01-06-1999
• Subjects: Adolescent; Adult; Aged; Alleles; Colitis, Ulcerative - genetics; Colitis, Ulcerative - physiopathology; Crohn Disease - genetics; Crohn Disease - physiopathology; Female; Humans; Inflammatory Bowel Diseases - genetics; Inflammatory Bowel Diseases - physiopathology; Interleukin-1 - genetics; Male; Middle Aged; Polymorphism, Genetic
• ISSN: 0093-7711; 1432-1211
• DOI: 10.1007/s002510050530

There is evidence of a disbalance in the inflammatory regulation of patients with inflammatory bowel diseases (IBD). Interleukin-1 beta plays an important role in the pro-inflammatory response. Our aim was to study the influence which IL1B gene polymorphisms may have on the severity and course of these diseases. Ninety-six patients with ulcerative colitis (UC), 98 patients with Crohn's disease (CD), and 132 ethnically matched healty individuals (HC) were typed for the polymorphic sites in the promoter region (position -511) and in exon 5 (position +3953) of the IL1B gene, using polymerase chain reaction (PCR)-based methods. In the CD group a significant association (P = 0.009) was found in this pair of genes. Homozygotes for allele 1 at position +3953 were more often present (69% vs 31%) in the subgroup of patients carrying at least one copy of allele 2 at position -511. This association was significant in patients with non-perforating disease (P = 0.002), but was not present in patients with perforating-fistulizing disease. The distribution of both allelic pairs in the non-fistulizing group proved to be significantly different from HC (P < 0.05), UC (P < 0.03), and the fistulizing group (P < 0.05). There was a similar association in non-operated patients (P = 0.024), whereas no such association was found in surgically treated patients. Among carriers of allele 2 at position -511, UC patients with more severe bleeding symptoms (P = 0.006) were less frequently found. These results suggest that IL1B gene polymorphisms participate in determining the course and severity of inflammatory bowel disease and contribute to explain the heterogeneity of these diseases.